Key result
Preoperative therapy was not an independent prognostic factor for cancer-specific or overall survival among 3,757 patients with pT1N0 rectal cancer compared to surgery alone.
Why the study?
It remained unclear whether rectal cancers downstaged by preoperative therapy show similar prognoses to those of the same stage without preoperative therapy.
Does preoperative therapy affect overall survival and cancer-specific survival in patients with pathologically confirmed T1N0 lower rectal cancer?
Cohort (n=3,757)
Yes
Does preoperative therapy affect overall survival and cancer-specific survival in patients with pathologically confirmed T1N0 lower rectal cancer?
Prognosis for pathologically confirmed T1N0 lower rectal cancer is similar regardless of whether patients received preoperative therapy.
No independent survival benefit seen with preoperative therapy in pT1N0 rectal cancer; leaves open need for randomized confirmation.
INTRODUCTION: Preoperative chemoradiotherapy (CRT) is the standard therapy for downstaging in locally advanced lower rectal cancer. However, it remains unclear whether rectal cancers downstaged by preoperative therapy show similar prognoses to those of the same stage without preoperative therapy. We previously demonstrated that preoperative CRT did not affect prognosis of rectal cancer with pathological T1N0 (pT1N0) stage in a single institute. Here, using a larger dataset, we compared prognoses of (y)pT1 rectal cancer stratified by the use of preoperative therapy and analyzed prognostic factors. METHODS: Cases of pT1N0 rectal cancer, registered between 2004 and 2016, were extracted from the Surveillance, Epidemiology, and End Results database. Patients were categorized as the "ypT1 group" if they had undergone preoperative therapy before surgery or as the "pT1 group" if they had undergone surgery alone. Overall survival (OS) and cancer-specific survival (CSS) between these groups of patients were compared. Factors associated with CSS and OS were identified by univariate and multivariate analyses. RESULTS: Among 3,757 eligible patients, ypT1 and pT1 groups comprised 720 and 3,037 patients, respectively. While ypT1 patients showed poorer CSS than ypT1 patients, there was no significant difference in OS. Preoperative therapy was not an independent prognostic factor for CSS or OS. Multivariate analysis identified age and histological type as significant factors associated with CSS. Sex, age, race, and number of lymph nodes dissected were identified as significant factors associated with OS. CONCLUSIONS: Prognosis among patients with (y)p T1N0 rectal cancer was similar irrespective of whether they underwent preoperative therapy, which is consistent with our previous observations.
No takes yet. Share an insight, caveat, or question.
Taira et al. (2021) conducted a cohort in pT1N0 rectal cancer (n=3,757). Preoperative therapy vs. Surgery alone was evaluated on Cancer-specific survival and overall survival. Preoperative therapy was not an independent prognostic factor for cancer-specific or overall survival among 3,757 patients with pT1N0 rectal cancer compared to surgery alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: